WebMay 25, 2024 · 该研究改良意向治疗人群(即mITT)非劣效性分析显示,甲苯磺酸艾多沙班片60 mg(若患者出现CrCl 30~50 ml/min、体重≤60 kg或合用强P-gp抑制剂,则需减量至30 mg)组主要有效性终点(卒中和体循环栓塞)不劣于华法林;甲苯磺酸艾多沙班片60 mg组较华法林降低大出血 ...
Hokusai-VTE研究:依杜沙班预防静脉血栓复发不劣于华法林
http://www.wikijournalclub.org/wiki/Hokusai-VTE WebFeb 27, 2014 · Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost. 2015 Nov … san francisco where\u0027s my ballot
Hokusai-VTE study suggests certain sub-groups EurekAlert!
Web在2项研究中,艾多沙班60 mg组最常见的出血相关不良反应(基于选定的术语)包括皮肤软组织出血(达5.9%)和鼻衄(达4.7%),而Hokusai-VTE研究最常见的出血相关不良反应为阴道出血(9.0%)。 出血可能发生在任意部位,可能为重度甚至致死(参见[注意事项])。 WebAug 4, 2016 · accp10专家组针对新型口服抗凝药物治疗vte原始文献以及荟萃分析认为:⑴达比加群、利伐沙班、阿哌沙班、依度沙班降低vte复发风险疗效与vka相似,包括合并恶性肿瘤患者;⑵合并恶性肿瘤患者,低分子肝素抗凝治疗降低血栓栓塞症复发风险疗效优于vka;⑶研究 ... WebJan 1, 2013 · The results of the Hokusai-VTE study indicate that in-hospital heparin for 5 days followed by edoxaban 60 mg daily is noninferior to warfarin in reducing recurrent VTEs in patients with acute VTE, and results in lower bleeding. This is an important study, and adds to data from studies such as EINSTEIN-PE, RE-COVER, and AMPLIFY. ... shortest eminem song